Zhaoke Ophthalmology Expands BRIMOCHOL PF Presbyopia Distribution to Singapore and Vietnam
Zhaoke Ophthalmology (HKG: 6622) announced expanded distribution agreements for BRIMOCHOL PF to include Singapore and...
Ophthalmology
Ocumension’s OT-703 DME Implant Enrolls 195 Patients in China Real-World Study
Ocumension Therapeutics (HKG: 1477) announced completion of enrollment for a real‑world study of OT-703 (fluocinonide...
Santen’s UPNEEQ Wins Japan Approval for Acquired Ptosis
Santen Pharmaceutical Co., Ltd. announced that UPNEEQ Mini 0.1% oxymetazoline solution (STN1013800) has been approved...
GenEditBio’s GEB-101 Wins FDA IND Approval as World’s First Corneal Gene Therapy
GenEditBio announced that GEB-101, its self‑developed in vivo genome editing investigational drug, has received Investigational...
Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China
Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that the first commercial batch of its...
Zhaoke BRIMOCHOL-PF Taiwan License Targets Presbyopia Market
Zhaoke Ophthalmology (HKG: 6622) announced it has granted TSH Biopharm (TW-8432) exclusive rights to register,...
Kexing GB10 nAMD Injection Secures NMPA Clinical Trial Approval
Kexing Biopharm (SHA: 688136) announced that its GB10 injection has received approval from China’s National...
Formosa Pharma APP13007 Clobetasol ASEAN Deal with Rxilient
Formosa Pharmaceuticals, Inc. (TPE: 6838) announced an exclusive licensing agreement with Rxilient Medical Pte. Ltd.,...
Boan Biotech’s Boyoujing Aflibercept Wins NMPA Approval for Retinal Diseases
Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that its self‑developed Aflibercept Intravitreal Injection (Boyoujing)...
Resight Therapeutics Secures Tens‑Millions RMB Angel Round to Accelerate iPSC‑Derived Corneal Endothelial Cell Therapy
Resight Therapeutics, a China‑based cell‑therapy pioneer founded in September 2024, announced the close of an Angel‑stage...
Gaush Meditech’s Subsidiary Secures China Registration for Integrated Ophthalmic Electrophysiology System
Gaush Meditech Ltd. (HKG: 2407) announced that its wholly‑owned subsidiary Gaush Tech Ltd. has been issued...
MeiraGTx Grants Eli Lilly Worldwide Rights to AAV‑AIPL1 Gene Therapy for LCA4
MeiraGTx Holdings plc (NASDAQ: MGTX) announced a strategic ophthalmology collaboration with Eli Lilly and Company...
Zhaoke Ophthalmology Indonesia Distribution Deal – BRIMOCHOL PF Eyes on Market Expansion
China‑listed Zhaoke Ophthalmology Ltd. (HKG: 6622) announced a new distribution and supply agreement with Indonesia’s...
4D Molecular Transfers Asia‑Pacific Gene‑Therapy Rights to Otsuka for $85 M Cash
4D Molecular Therapeutics (4DMT) sold the Asia‑Pacific rights to its eye‑gene therapy 4D‑150 to Otsuka...
GenAns Biotechnology Receives FDA Fast‑Track Designation for GA001 Injection, a Promising Gene‑Therapy for Retinitis Pigmentosa
China‑based GenAns Biotechnology Co., Ltd. announced that its proprietary gene‑therapy drug GA001 injection received Fast‑Track...
Everest Medicines Secures Exclusive Rights to VIS‑101 in Greater China, Potential 2026 Phase 3 Launch
Hong Kong‑listed Everest Medicines Limited (HKG: 1952) today announced a strategic agreement with Visara, Inc.,...
Grand Pharma Launches GPN00884 Clinical Trial to Tackle Pediatric Myopia Progression
Grand Pharmaceutical Group Limited (HKG: 0512), a China-based company, announced on October 26, 2025, that...
Eli Lilly to Acquire Adverum Biotechnologies for Up to USD 261.7m for Ixo-vec Access
Eli Lilly (NYSE: LLY) announced on October 24, 2025, that it will acquire gene therapy...
Novartis Transfers Lucentis and Beovu Rights to CMS Vision in China Deal
Novartis (NYSE: NVS) announced on October 27, 2025, the signing of a strategic cooperation agreement...
Ollin Biosciences Launches With $100M Funding to Advance Ophthalmology Pipeline
Ollin Biosciences, Inc. (Ollin), a clinical-stage biopharmaceutical company, announced its launch on September 16, 2025,...